Glenmark Pharmaceuticals Ltd (GLENMARK) — Announcement | 23 September 2026

23 September 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Glenmark receives FDA VAI classification for Goa facility

💡 Investor Takeaway

The VAI status signals a regulatory issue but does not indicate immediate financial loss or production halt.

Glenmark Pharmaceuticals announced it received a Voluntary Action Indicated (VAI) classification from the U.S. FDA for its Goa formulations manufacturing facility following an inspection conducted June 22-30, 2026. The filing confirms the VAI status but provides no financial impact, revised guidance, or new risk disclosures. The company highlighted its global R&D and manufacturing scale but did not specify corrective actions or timelines.

📄 View Original Announcement (PDF)

📊 Stock Analysis — GLENMARK ✨ Ask AI About This

About Glenmark Pharmaceuticals Ltd (GLENMARK)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹65,922.11 CrP/E: 36.7ROE: 17.1%ROCE: 24.6%Div Yield: 0.11%

View full GLENMARK stock details →

📡 Get AI alerts when GLENMARK files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLENMARK — Free

💡 Ask AI about this filing

"What specific corrective actions must Glenmark implement for the VAI?""How does this FDA finding affect future U.S. product launches?""What is the expected timeline for resolving the VAI classification?"

Ask AI Free →

📊 More GLENMARK filings

Announcement — 28 September 2026Glenmark Pharmaceuticals announced that its trading window for insider transactions will close on Oc...
🔴 Announcement — 21 September 2026Glenmark Pharmaceuticals announced its schedule for upcoming analyst and institutional investor meet...
🟡 Voting Results — 11 September 2026Glenmark Pharmaceuticals held its 48th AGM on September 11, 2026 via video conference, approving aud...
🔴 Announcement — 11 September 2026Glenmark Pharmaceuticals announced the launch of RYALTRIS Nasal Spray in Brazil for allergic rhiniti...
🟡 Board Meeting — 11 September 2026Glenmark Pharmaceuticals held its 48th AGM on September 11, 2026 via video conferencing, where share...

See all GLENMARK filings →

🔥 Also filed on 23 September 2026

PFOCUSPrime Focus LtdAnnouncement 501261Lords Mark Industries LimitedAnnouncement GREENPOWEROrient Green Power Company LtdCorporate Action PFOCUSPrime Focus LtdAnnouncement GSFCGujarat State Fertilizers & Chemicals LtdAnnouncement OSWALPUMPSOswal Pumps LtdAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLENMARK files new disclosures

Track GLENMARK filings, board meetings, and corporate actions. Free email alerts at 5 PM.